You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

~ Buy the KENGREAL (cangrelor) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR KENGREAL


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Kengreal

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02978040 ↗ Randomized Comparison of Cangrelor, Tirofiban and Prasugrel in Patients With STEMI Referred for Primary PCI. Completed University Hospital Inselspital, Berne Phase 4 2017-07-04 Primary percutaneous coronary intervention (PCI) is the main reperfusion therapy in patients with ST-elevation myocardial infarction (STEMI). The optimal platelet inhibition at the time of PCI is fundamental, however, the comparative speed of action of cangrelor as opposed to tirofiban and to chewed or integer loading dose of prasugrel is unknown. The purpose of this trial is to assess the inhibition of platelet aggregation with different regimens on platelet inhibition (tirofiban bolus+infusion, cangrelor bolus+infusion, prasugrel chewed loading dose, prasugrel integer loading dose) in the early phase of primary PCI.
NCT03043274 ↗ Cangrelor in ST-Elevation Myocardial Infarction to Decrease Infarct Size Terminated George Bennet, MD Phase 4 2017-01-01 This study evaluates differences in the extent of myocardial necrosis noted by cardiac MRI in patients with ST-elevation myocardial infarction randomized to receive cangrelor during their percutaneous coronary intervention and compares them to patients randomized to not receive cangrelor.
NCT03043274 ↗ Cangrelor in ST-Elevation Myocardial Infarction to Decrease Infarct Size Terminated Khaled Ziada, MD Phase 4 2017-01-01 This study evaluates differences in the extent of myocardial necrosis noted by cardiac MRI in patients with ST-elevation myocardial infarction randomized to receive cangrelor during their percutaneous coronary intervention and compares them to patients randomized to not receive cangrelor.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Kengreal

Condition Name

Condition Name for Kengreal
Intervention Trials
Coronary Artery Disease 3
STEMI - ST Elevation Myocardial Infarction 3
Acute Coronary Syndrome 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Kengreal
Intervention Trials
Myocardial Infarction 3
Infarction 3
Coronary Artery Disease 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Kengreal

Trials by Country

Trials by Country for Kengreal
Location Trials
United States 3
Switzerland 1
Denmark 1
Italy 1
Singapore 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Kengreal
Location Trials
Florida 2
Kentucky 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Kengreal

Clinical Trial Phase

Clinical Trial Phase for Kengreal
Clinical Trial Phase Trials
Phase 4 5
Phase 2 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Kengreal
Clinical Trial Phase Trials
Recruiting 2
Unknown status 2
Terminated 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Kengreal

Sponsor Name

Sponsor Name for Kengreal
Sponsor Trials
Scott R MacKenzie Foundation 2
Scott R. MacKenzie Foundation 2
University of Florida 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Kengreal
Sponsor Trials
Other 14
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.